Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes (diagnosed clinically) for 24 weeks or longer prior to randomisation (visit 2)~* Insulin naïve subjects (Allowed are: Previous short term insulin treatment no longer than or equal to 14 days in total; Treatment during hospitalisation or during gestational diabetes is allowed for periods longer than 14 days in total)~* Current treatment: Metformin alone or metformin in any combination of 1 or 2 additional OADs (oral anti-diabetic drug) including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitors, alpha-glucosidase inhibitors or thiazolidinediones (TZDs) - all with unchanged dosing for at least 12 weeks prior to randomisation (visit 2). Metformin dose, alone or in combination (including fixed combination), must be at least 1000 mg daily~* HbA1c (glycosylated haemoglobin) 7.0-10.0% (both inclusive)~* BMI (Body Mass Index) below or equal to 45 kg/m\^2~* Ability and willingness to adhere to the protocol including self measurement of plasma glucose~Exclusion Criteria:~* Treatment with GLP-1 (glucagon like peptide) receptor agonists within the last 12 weeks prior to randomisation (visit 2)~* Recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator (trial physician)~* Previous participation in this trial. Participation is defined as randomised. Re-screening is allowed once during the recruitment period~* Known or suspected hypersensitivity to trial products or related products~* The receipt of any investigational drug within 4 weeks prior to randomisation (visit 2)~* Anticipated significant lifestyle changes during the study, e.g. shift work (including permanent night/evening shift workers) as well as highly variable eating habits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDegAsp Simple (Type: EXPERIMENTAL): None
- IDegAsp Step wise (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).